


RealRate

PHARMACEUTICAL 2021

LUMOS PHARMA INC. Rank 29 of 402









RealRate

PHARMACEUTICAL 2021

LUMOS PHARMA INC. Rank 29 of 402



The relative strengths and weaknesses of LUMOS PHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LUMOS PHARMA INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of LUMOS PHARMA INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 275%, being 228% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	128,449
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,461
Liabilities, Non-Current	6,000
Other Assets	249
Other Compr. Net Income	0
Other Expenses	-13,973
Other Liabilities	0
Other Net Income	6,667
Other Revenues	168
Property and Equipment	335
Research and Development	9,206
Selling, General and Administrative Expense	17,265

Output Variable	Value in 1000 USD
Assets	129,033
Liabilities	12,461
Expenses	12,498
Revenues	168
Stockholders Equity	116,572
Net Income	-5,663
Comprehensive Net Income	-5,663
Economic Capital Ratio	275%

